Augmedix

Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. It offers live support including referrals, orders, and reminders that allow clinicians to focus on patient care. The company was founded by Ian Shakil in 2012 and is headquartered in San Francisco, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Augmedix reports record Q4 earnings, eyes growth in healthcare tech

Augmedix demonstrated robust performance in Q4 2022 with strong revenue growth and bookings.
The company's strategic focus on product development and expansion into new markets bodes well for future growth.
While facing challenges in expenses and competition, Augmedix's opportunities for growth are significant.
Investors can be optimistic about Augmedix's outlook given its solid financial performance and growth prospects.

Augmedix reports robust Q1 growth, eyes profitability amid rising expenses

Augmedix demonstrated strong revenue growth, customer retention, and cost management in Q1 2023.
While facing challenges such as increasing expenses and cash outflows, the company remains focused on achieving profitability.
With a solid financial position and growth opportunities ahead, Augmedix is poised for continued success in the healthcare technology sector.

Augmedix reports robust Q2 growth, raises revenue guidance for 2023

Augmedix's Q2 performance reflects strong revenue growth, margin expansion, and strategic partnerships driving market positioning. While facing challenges in managing expenses and achieving profitability, the company remains optimistic about its growth trajectory. Augmedix's focus on innovation and capacity expansion positions it well to capitalize on opportunities for sustained revenue growth and market competitiveness.

Augmedix reports strong Q3 earnings, introduces AI app for clinicians

Augmedix demonstrated robust financial growth and operational improvements in Q3 2023, positioning itself for continued success.
The company's innovative product offerings and strategic partnerships underscore its commitment to driving healthcare efficiency.
While facing challenges such as product adoption ramp-up and regulatory compliance, Augmedix remains focused on growth and innovation.

Augmedix reports robust Q4 earnings, eyes growth in healthcare tech

Augmedix's strong financial performance in Q4 2023 reflects revenue growth, improved EBITDA, and strategic cost management, positioning the company for future success.
Diverse product offerings, positive partnerships, and efficient capital deployment are key strengths driving Augmedix's growth trajectory and market competitiveness.
While facing profitability challenges and the need for revenue diversification, Augmedix has significant opportunities in the expanding healthcare technology market and strong market demand for its products.

Augmedix reports robust Q1 growth, eyes AI-first SaaS transition

Augmedix's Q1 performance reflects strong revenue growth and strategic product launches, despite challenges in revenue outlook and increased expenses.
The company's focus on transitioning to an AI-first SaaS model and leveraging partnerships like HCA Healthcare positions it for future growth.
Optimism about clinical adoption and a commitment to reaching cash flow breakeven by 2025 highlight Augmedix's long-term strategic vision.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced it will report financial results for the first quarter of 2022 on Monday, May 9, 2022, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Augmedix to Report First Quarter 2022 Financial Results on May 9, 2022

SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced the company will be participating in the upcoming Lytham Partners Investors Conference, which will take place virtually from April 4 to April 7, 2022.

Augmedix to Participate at the 2022 Lytham Partners Spring Investor Conference

Augmedix, Inc. (AUGX) CEO Manny Krakaris on Q4 2021 Results - Earnings Call Transcript

SAN FRANCISCO, March 21, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended December 31, 2021.

Augmedix Reports Fourth Quarter and Full Year 2021 Financial Results

SAN FRANCISCO, March 07, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced it will report financial results for the fourth quarter and full year 2021 on Monday, March 21, 2022, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Augmedix to Report Fourth Quarter and Full Year 2021 Financial Results on March 21, 2022

SAN FRANCISCO, March 01, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced the company will be presenting in the upcoming JMP Securities Technology Conference in San Francisco.

Augmedix to Participate at the 2022 JMP Securities Technology Conference

SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced preliminary unaudited financial and operational results for the three months ended December 31, 2021.

Augmedix Announces Preliminary Fourth Quarter 2021 Financial Results

Augmedix drives its revenue growth by reducing burnout of physicians who are highly productive.

Augmedix: A Splendid Long-Term Investing Opportunity

SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced the company will be participating in the upcoming 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5 to 7, 2022.

Augmedix to Participate at the 11th Annual LifeSci Partners Corporate Access Event

American Rheumatology Network announces partnership with Augmedix to scale the use of Augmedix to community rheumatology practices across the nation American Rheumatology Network announces partnership with Augmedix to scale the use of Augmedix to community rheumatology practices across the nation

American Rheumatology Network Announces Partnership with Augmedix

NEW YORK, Dec. 08, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Augmedix Inc. (NASDAQ: AUGX ) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

Augmedix Inc. (NASDAQ: AUGX) Leveraging ASR, NLP Tech to Rehumanize Healthcare

Augmedix celebrates successful uplisting to Nasdaq and public offering Augmedix celebrates successful uplisting to Nasdaq and public offering

Augmedix, Inc. to Ring Nasdaq Closing Bell Today

Krakaris and Bartiromo discuss how Augmedix solves physician medical documentation challenges Krakaris and Bartiromo discuss how Augmedix solves physician medical documentation challenges

Augmedix, Inc. CEO Appears On Fox Business Network Show

SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading digital health platform that offers virtual medical documentation and live clinical support, today reported financial results for the three months ended September 30, 2021.

Augmedix Reports Third Quarter 2021 Financial Results

Virtual healthcare service and health association partner to reduce the burden of documentation across rural health networks Virtual healthcare service and health association partner to reduce the burden of documentation across rural health networks

Augmedix Partners with the National Cooperative of Health Networks Association

E2open Parent Holdings

The first several days of November saw insiders spend nearly $750 million buying up shares of their companies, which is worth your attention. The post 2 Moonshots That Insiders Are Buying… and 3 They're Not appeared first on InvestorPlace.

2 Moonshots That Insiders Are Buying… and 3 They're Not

Arteris

AirSculpt Technologies

Aura Biosciences

Solo Brands

Fluence Energy

GlobalFoundries

HireRight GIS Group Holdings LLC

LF Capital Acquisition Corp II

Marpai

Rent the Runway

Sonendo

Entrada Therapeutics

Udemy

Sweetgreen

The IPO market remained active this past week as 13 IPOs raised $6.3 billion. SPAC activity kept steady with 13 blank check IPOs raising $2.1 billion.

U.S. IPO Weekly Recap: Semiconductors And Energy Storage Lead A Spooky 14 IPO Week

SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced it will report financial results for the third quarter 2021 on Tuesday, November 9, 2021, after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Augmedix to Report 2021 Third Quarter Financial Results on November 9, 2021

SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX) ("Augmedix"), a leading provider of virtual medical documentation and live clinical support, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock (“Common Stock”) at a public offering price of $4.00 per share. In addition, Augmedix has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Common Stock at the public offering price less the underwriting discounts and commissions. Gross proceeds from the offering before expenses and underwriting commissions are expected to be $40,000,000.00. The offering is expected to close on or about October 28, 2021 subject to customary closing conditions. Augmedix plans to use the net proceeds it receives from the offering to fund increased investment in sales and marketing, research and development and general and administrative costs as Augmedix increases its scale.

Augmedix, Inc. Announces Uplisting to Nasdaq and Pricing of Public Offering of $40,000,000 of Common Stock

SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (OTCQX: AUGX) (“Augmedix”), a leading provider of virtual medical documentation and live clinical support, today announced the launch of its underwritten offering of $40,000,000 of shares of its common stock. Augmedix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of common stock that are sold in the offering. Augmedix has applied to list its common stock on the Nasdaq Capital Market under the ticker symbol “AUGX.”

Augmedix Announces Launch of Underwritten Offering

SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (OTCQX: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced preliminary unaudited financial and operational results for the three months ended September 30, 2021.

Augmedix Announces Preliminary Third Quarter 2021 Financial Results

Augmedix has filed to raise $40 million in a U.S. uplisting IPO to Nasdaq, although the final amount may differ.

Augmedix Begins U.S. Uplisting IPO Effort

SAN FRANCISCO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (OTCQX: AUGX), a leading provider of virtual medical documentation and live clinical support, today reported financial results for the three months ended June 30, 2021.

Augmedix Reports Second Quarter 2021 Financial Results

Collaboration will Bring Augmedix's Solution to Physicians Nationwide – Alleviating Burnout, Increasing Efficiency, and Improving Patient Experience Collaboration will Bring Augmedix's Solution to Physicians Nationwide – Alleviating Burnout, Increasing Efficiency, and Improving Patient Experience

Augmedix Announces Partnership with Medical Advantage

SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- Augmedix, Inc. (OTCQX: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced it will report financial results for the second quarter 2021 on Tuesday, August 10, 2021 after market close. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

News for Augmedix Stock (AUGX)